Literature DB >> 19282420

Conditioned place preference and locomotor activity in response to methylphenidate, amphetamine and cocaine in mice lacking dopamine D4 receptors.

P K Thanos1, C Bermeo, M Rubinstein, K L Suchland, G J Wang, D K Grandy, N D Volkow.   

Abstract

Methylphenidate (MP) and amphetamine (AMPH) are the most frequently prescribed medications for the treatment of attention-deficit/hyperactivity disorder (ADHD). Both drugs are believed to derive their therapeutic benefit by virtue of their dopamine (DA)-enhancing effects, yet an explanation for the observation that some patients with ADHD respond well to one medication but not to the other remains elusive. The dopaminergic effects of MP and AMPH are also thought to underlie their reinforcing properties and ultimately their abuse. Polymorphisms in the human gene that codes for the DA D4 receptor (D4R) have been repeatedly associated with ADHD and may correlate with the therapeutic as well as the reinforcing effects of responses to these psychostimulant medications. Conditioned place preference (CPP) for MP, AMPH and cocaine were evaluated in wild-type (WT) mice and their genetically engineered littermates, congenic on the C57Bl/6J background, that completely lack D4Rs (knockout or KO). In addition, the locomotor activity in these mice during the conditioning phase of CPP was tested in the CPP chambers. D4 receptor KO and WT mice showed CPP and increased locomotor activity in response to each of the three psychostimulants tested. D4R differentially modulates the CPP responses to MP, AMPH and cocaine. While the D4R genotype affected CPP responses to MP (high dose only) and AMPH (low dose only) it had no effects on cocaine. Inasmuch as CPP is considered an indicator of sensitivity to reinforcing responses to drugs these data suggest a significant but limited role of D4Rs in modulating conditioning responses to MP and AMPH. In the locomotor test, D4 receptor KO mice displayed attenuated increases in AMPH-induced locomotor activity whereas responses to cocaine and MP did not differ. These results suggest distinct mechanisms for D4 receptor modulation of the reinforcing (perhaps via attenuating dopaminergic signalling) and locomotor properties of these stimulant drugs. Thus, individuals with D4 receptor polymorphisms might show enhanced reinforcing responses to MP and AMPH and attenuated locomotor response to AMPH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19282420      PMCID: PMC2878389          DOI: 10.1177/0269881109102613

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  69 in total

Review 1.  Dopamine D4 receptors.

Authors:  D M Helmeste; S W Tang
Journal:  Jpn J Pharmacol       Date:  2000-01

2.  Ethanol-conditioned place preference is reduced in dopamine D2 receptor-deficient mice.

Authors:  C L Cunningham; M A Howard; S J Gill; M Rubinstein; M J Low; D K Grandy
Journal:  Pharmacol Biochem Behav       Date:  2000-12       Impact factor: 3.533

Review 3.  Dopamine genes and attention-deficit hyperactivity disorder: a review.

Authors:  Salvatore DiMaio; Nathalie Grizenko; Ridha Joober
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

4.  The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus.

Authors:  E Wang; Y-C Ding; P Flodman; J R Kidd; K K Kidd; D L Grady; O A Ryder; M A Spence; J M Swanson; R K Moyzis
Journal:  Am J Hum Genet       Date:  2004-04-09       Impact factor: 11.025

5.  Cocaine-induced locomotor activity and cocaine discrimination in dopamine D4 receptor mutant mice.

Authors:  Jonathan L Katz; Allison L Chausmer; Gregory I Elmer; Marcelo Rubinstein; Malcolm J Low; David K Grandy
Journal:  Psychopharmacology (Berl)       Date:  2003-05-29       Impact factor: 4.530

6.  Concurrent evaluation of locomotor response to novelty and propensity toward cocaine conditioned place preference in mice.

Authors:  Kazuaki Shimosato; Satoru Watanabe
Journal:  J Neurosci Methods       Date:  2003-09-30       Impact factor: 2.390

7.  Dopamine D4 receptor-deficient mice, congenic on the C57BL/6J background, are hypersensitive to amphetamine.

Authors:  Paul J Kruzich; Katherine L Suchland; David K Grandy
Journal:  Synapse       Date:  2004-08       Impact factor: 2.562

8.  The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder.

Authors:  M E Avale; T L Falzone; D M Gelman; M J Low; D K Grandy; M Rubinstein
Journal:  Mol Psychiatry       Date:  2004-07       Impact factor: 15.992

Review 9.  Dopamine phenotype and behaviour in animal models: in relation to attention deficit hyperactivity disorder.

Authors:  Davide Viggiano; Lucia A Ruocco; Adolfo G Sadile
Journal:  Neurosci Biobehav Rev       Date:  2003-11       Impact factor: 8.989

10.  High prevalence of rare dopamine receptor D4 alleles in children diagnosed with attention-deficit hyperactivity disorder.

Authors:  D L Grady; H-C Chi; Y-C Ding; M Smith; E Wang; S Schuck; P Flodman; M A Spence; J M Swanson; R K Moyzis
Journal:  Mol Psychiatry       Date:  2003-05       Impact factor: 15.992

View more
  20 in total

1.  Dopamine D4 receptors modulate brain metabolic activity in the prefrontal cortex and cerebellum at rest and in response to methylphenidate.

Authors:  Michael Michaelides; Javier Pascau; Juan-Domingo Gispert; Foteini Delis; David K Grandy; Gene-Jack Wang; Manuel Desco; Marcelo Rubinstein; Nora D Volkow; Panayotis K Thanos
Journal:  Eur J Neurosci       Date:  2010-07-16       Impact factor: 3.386

2.  Potential serotonin 5-HT(1A) and dopamine D(4) receptor modulation of the discriminative stimulus effects of amphetamine in rats.

Authors:  Danuta Marona-Lewicka; David E Nichols
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

3.  PET imaging predicts future body weight and cocaine preference.

Authors:  Michael Michaelides; Panayotis K Thanos; Ronald Kim; Jacob Cho; Mala Ananth; Gene-Jack Wang; Nora D Volkow
Journal:  Neuroimage       Date:  2011-08-26       Impact factor: 6.556

Review 4.  Dopamine D4 receptors in psychostimulant addiction.

Authors:  Patricia Di Ciano; David K Grandy; Bernard Le Foll
Journal:  Adv Pharmacol       Date:  2014

5.  The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding.

Authors:  Jared W Young; Susan B Powell; Christine N Scott; Xianjin Zhou; Mark A Geyer
Journal:  Behav Brain Res       Date:  2011-03-31       Impact factor: 3.332

6.  Self-administration of agonists selective for dopamine D2, D3, and D4 receptors by rhesus monkeys.

Authors:  Mikhail N Koffarnus; Gregory T Collins; Kenner C Rice; Jianyong Chen; James H Woods; Gail Winger
Journal:  Behav Pharmacol       Date:  2012-08       Impact factor: 2.293

Review 7.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

8.  A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior.

Authors:  Panayotis K Thanos; Lisa S Robison; Jessica Steier; Yu Fen Hwang; Thomas Cooper; James M Swanson; David E Komatsu; Michael Hadjiargyrou; Nora D Volkow
Journal:  Pharmacol Biochem Behav       Date:  2015-01-29       Impact factor: 3.533

9.  Differential effects of methylphenidate and cocaine on GABA transmission in sensory thalamic nuclei.

Authors:  Belén Goitia; Mariana Raineri; Laura E González; José L Rozas; Edgar Garcia-Rill; Verónica Bisagno; Francisco J Urbano
Journal:  J Neurochem       Date:  2013-01-07       Impact factor: 5.372

10.  Dopamine D4 receptor (D4R) deletion in mice does not affect operant responding for food or cocaine.

Authors:  Panayotis K Thanos; Rahila Habibi; Michael Michaelides; Ujval B Patel; Katherine Suchland; Brenda J Anderson; John K Robinson; Gene-Jack Wang; David K Grandy; Nora D Volkow
Journal:  Behav Brain Res       Date:  2009-10-22       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.